BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 16856436)

  • 1. An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
    Boon-yasidhi V; Kim YS; Scahill L
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S156-62. PubMed ID: 16856436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
    Scahill L; Chappell PB; Kim YS; Schultz RT; Katsovich L; Shepherd E; Arnsten AF; Cohen DJ; Leckman JF
    Am J Psychiatry; 2001 Jul; 158(7):1067-74. PubMed ID: 11431228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study.
    Cubo E; Fernández Jaén A; Moreno C; Anaya B; González M; Kompoliti K
    Clin Ther; 2008 Jan; 30(1):182-9. PubMed ID: 18343255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience.
    Chappell PB; Riddle MA; Scahill L; Lynch KA; Schultz R; Arnsten A; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1995 Sep; 34(9):1140-6. PubMed ID: 7559307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
    Allen AJ; Kurlan RM; Gilbert DL; Coffey BJ; Linder SL; Lewis DW; Winner PK; Dunn DW; Dure LS; Sallee FR; Milton DR; Mintz MI; Ricardi RK; Erenberg G; Layton LL; Feldman PD; Kelsey DK; Spencer TJ
    Neurology; 2005 Dec; 65(12):1941-9. PubMed ID: 16380617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine.
    Singer HS; Brown J; Quaskey S; Rosenberg LA; Mellits ED; Denckla MB
    Pediatrics; 1995 Jan; 95(1):74-81. PubMed ID: 7770313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
    Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
    Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL; Sahl R; Hardan AY
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder.
    Hunt RD; Arnsten AF; Asbell MD
    J Am Acad Child Adolesc Psychiatry; 1995 Jan; 34(1):50-4. PubMed ID: 7860456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.
    Lombroso PJ; Scahill L; King RA; Lynch KA; Chappell PB; Peterson BS; McDougle CJ; Leckman JF
    J Am Acad Child Adolesc Psychiatry; 1995 Sep; 34(9):1147-52. PubMed ID: 7559308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD.
    Ambrosini PJ; Sallee FR; Lopez FA; Shi L; Michaels MA;
    Curr Med Res Opin; 2006 Feb; 22(2):427-40. PubMed ID: 16466615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
    Niederhofer H; Staffen W; Mair A
    J Psychopharmacol; 2003 Mar; 17(1):113-9. PubMed ID: 12680748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder.
    Gadow KD; Sverd J; Nolan EE; Sprafkin J; Schneider J
    J Am Acad Child Adolesc Psychiatry; 2007 Jul; 46(7):840-8. PubMed ID: 17581448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of quality of life in children with Gilles de la Tourette syndrome.
    Bernard BA; Stebbins GT; Siegel S; Schultz TM; Hays C; Morrissey MJ; Leurgans S; Goetz CG
    Mov Disord; 2009 May; 24(7):1070-3. PubMed ID: 19306279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.